Stockscreener 앱 받기
18.75
3.10%
-0.60
시간 외 거래:
16.78
-1.97
-10.51%
전일 마감가:
$19.35
열려 있는:
$19.4
하루 거래량:
535.30K
Relative Volume:
1.28
시가총액:
$579.49M
수익:
$219.79M
순이익/손실:
$-57.47M
주가수익비율:
-8.7209
EPS:
-2.15
순현금흐름:
$-19.25M
1주 성능:
-6.67%
1개월 성능:
+0.97%
6개월 성능:
-39.81%
1년 성능:
-22.93%
1일 변동 폭
$18.69
$19.67
1주일 범위
$18.69
$20.32
52주 변동 폭
$16.96
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
명칭
Castle Biosciences Inc
전화
866-788-9007
주소
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
CSTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
18.75 | 579.49M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
422.27 | 159.05B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.40 | 140.21B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
475.07 | 34.90B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
108.37 | 30.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
152.30 | 26.47B | 15.41B | 1.37B | 2.11B | 7.50 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2021-04-30 | 개시 | Lake Street | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | 재확인 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | BTIG Research | Buy |
| 2019-08-19 | 개시 | Canaccord Genuity | Buy |
| 2019-08-19 | 개시 | Robert W. Baird | Outperform |
| 2019-08-19 | 개시 | SVB Leerink | Outperform |
모두보기
Castle Biosciences Inc 주식(CSTL)의 최신 뉴스
Earnings call transcript: Castle Biosciences Q1 2025 revenue growth surpasses expectations - Investing.com Australia
Castle Biosciences (CSTL) to Acquire Gastrointestinal Firm Previse | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Adjusts 2025 Revenue Outlook | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Exceeds Revenue Expectations in Q1 | CSTL Stock News - GuruFocus
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Castle Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Castle Biosciences Reports 21% Revenue Increase in Q1 2025 - TipRanks
Castle Biosciences to buy Previse (CSTL:NASDAQ) - Seeking Alpha
Castle Biosciences To Acquire Previse - marketscreener.com
Castle Biosciences to Acquire Previse | CSTL Stock News - GuruFocus
Castle Biosciences to Acquire Previse for GI Test Expansion - Investing.com
Castle Biosciences Reports First Quarter 2025 Results | CSTL Stock News - GuruFocus
Castle Biosciences Reports First Quarter 2025 Results - GlobeNewswire
Castle Biosciences to Acquire Previse - GlobeNewswire
Castle Biosciences to Acquire Previse - Benzinga
Castle Biosciences Acquires Johns Hopkins-Backed GI Health Company Previse to Transform Cancer Detection - Stock Titan
Wells Fargo & Company MN Boosts Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Barclays PLC Sells 3,288 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Invesco Ltd. Raises Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences (CSTL) Expected to Announce Quarterly Earnings on Monday - Defense World
New Data at DDW 2025 Further Demonstrates the TissueCypher® - GlobeNewswire
New Clinical Data Reveals How TissueCypher Test Could Transform Early Esophageal Cancer Detection - Stock Titan
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Report Preview: W - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Rating of “Buy” by Brokerages - Defense World
New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Ou - GuruFocus
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity - GlobeNewswire
DecisionDx-Melanoma Test Achieves 97.2% Accuracy in Identifying Low-Risk Melanoma Patients - Stock Titan
Legal & General Group Plc Sells 6,356 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences' DecisionDx-Melanoma Test Orders Reach 200,000 - marketscreener.com
Castle Biosciences (CSTL) Reaches Key Milestone with Melanoma Te - GuruFocus
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma - GlobeNewswire
Melanoma Diagnostic Breakthrough: DecisionDx Test Hits 200,000 Orders, Backed by 50+ Clinical Studies - Stock Titan
Envestnet Asset Management Inc. Increases Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Russell Investments Group Ltd. Has $192,000 Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Me - GuruFocus
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis - The Manila Times
Castle Biosciences to Present Research on Melanoma Patient Care at AACR Annual Meeting 2025 - Nasdaq
New Data at AACR Annual Meeting Highlights Use of - GlobeNewswire
Closing Figures Unveiled: Castle Biosciences Inc (CSTL) Drop -1.60, Closes at 20.93 - DWinneX
How did Castle Biosciences Inc (CSTL) fare last session? - uspostnews.com
Castle Biosciences (NASDAQ:CSTL) Stock Price Down 3.9% After Insider Selling - Defense World
LPL Financial LLC Has $614,000 Stake in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
JPMorgan Chase & Co. Grows Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences, Inc. (NASDAQ:CSTL) Stake Raised by Geode Capital Management LLC - Defense World
CSTL’s Stock Market Adventure: -19.29% YTD Growth Amidst Volatility - investchronicle.com
When Should You Buy Castle Biosciences, Inc. (NASDAQ:CSTL)? - simplywall.st
Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern - Seeking Alpha
Castle Biosciences to Release First Quarter 2025 Financial Resul - GuruFocus
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025 - GlobeNewswire
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Acquired by Franklin Resources Inc. - Defense World
28,903 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Acquired by Arrowstreet Capital Limited Partnership - Defense World
Castle Biosciences Inc (CSTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.34%
0.46%
자본화:
|
볼륨(24시간):